LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), announced today that it has begun dosing in the First-in-Human clinical trial with CB-183,315, an investigational antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile associated diarrhea, or CDAD. CB-183,315 is a novel antibacterial agent discovered by Cubist scientists that has potent bactericidal activity against C. difficile bacteria and has demonstrated preclinical safety and efficacy in animal models. The IND for CB-183,315 was submitted to the FDA in December 2008.
